Xeris Biopharma (XERS) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XERS shares.
View XERS analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued twelve-month target prices for Xeris Biopharma's shares. Their XERS share price forecasts range from $4.00 to $6.00. On average, they expect the company's share price to reach $4.88 in the next twelve months. This suggests a possible upside of 170.8% from the stock's current price.
View analysts price targets for XERS or view top-rated stocks among Wall Street analysts.

Xeris Biopharma's stock was trading at $1.33 at the beginning of 2023. Since then, XERS stock has increased by 35.3% and is now trading at $1.80.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our XERS earnings forecast.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) issued its earnings results on Tuesday, August, 8th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The firm earned $38.01 million during the quarter, compared to analysts' expectations of $34.84 million. Xeris Biopharma had a negative trailing twelve-month return on equity of 191.02% and a negative net margin of 53.28%.

iShares Neuroscience and Healthcare ETF holds 15,969 shares of XERS stock, representing 0.79% of its portfolio.

Xeris Biopharma updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $145.00 million-$165.00 million, compared to the consensus revenue estimate of $149.35 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and Organigram (OGI).

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager.

Xeris Biopharma trades on the NASDAQ under the ticker symbol "XERS."

Xeris Biopharma's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.89%), Caxton Corp (4.09%), Stonepine Capital Management LLC (3.98%), Geode Capital Management LLC (1.98%), State Street Corp (1.84%) and Northern Trust Corp (0.85%). Insiders that own company stock include Paul R Edick and Steven Prestrelski.
View institutional ownership trends.

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XERS stock can currently be purchased for approximately $1.80.

Xeris Biopharma (NASDAQ:XERS) has a market capitalization of $248.52 million and generates $134.07 million in revenue each year. The company earns $-94,660,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

The company employs 355 workers across the globe.

Xeris Biopharma's mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The official website for the company is www.xerispharma.com. The company can be reached via phone at (844) 445-5704 or via email at ir@xerispharma.com.